Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven, PA. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, SA. Im, K. Petrakova, GV. Bianchi, M. Martín, A. Nusch, GS. Sonke, L. De la Cruz-Merino, JT. Beck, JP. Zarate, Y. Wang, A. Chakravartty, C. Wang, DJ. Slamon

. 2023 ; 25 (1) : 103. [pub] 20230831

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016474

BACKGROUND: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in the final protocol-specified and exploratory (longer follow-up) OS analyses. At the time of these analyses, the full OS benefit of 1L ribociclib was not completely characterized because the median OS (mOS) was not reached. As CDK4/6 inhibitor (CDK4/6i) + endocrine therapy (ET) is now a preferred option for 1L HR+/HER2- ABC, we report an exploratory analysis (median follow-up, 70.8 months; 14.5 months longer than the prior analysis) to fully elucidate the OS benefit in the MONALEESA-3 1L population. METHODS: Postmenopausal patients with HR+/HER2- ABC were randomized 2:1 to 1L/2L fulvestrant + ribociclib or placebo. OS in 1L patients (de novo disease or relapse > 12 months from completion of [neo]adjuvant ET) was assessed by Cox proportional hazards model and Kaplan-Meier methods. Progression-free survival 2 (PFS2) and chemotherapy-free survival (CFS) were analyzed. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615). RESULTS: At data cutoff (January 12, 2022; median follow-up time, 70.8 months), mOS was 67.6 versus 51.8 months with 1L ribociclib versus placebo (hazard ratio (HR) 0.67; 95% CI 0.50-0.90); 16.5% and 8.6% of ribociclib and placebo patients, respectively, were still receiving treatment. PFS2 (HR 0.64) and CFS (HR 0.62) favored ribociclib versus placebo. Among those who discontinued treatment, 16.7% and 35.0% on ribociclib or placebo, respectively, received a subsequent CDK4/6i. No new safety signals were observed. CONCLUSIONS: This analysis of MONALEESA-3 reports the longest mOS thus far (67.6 months) for 1L patients in a phase III ABC trial. These results in a 1L population show that the OS benefit of ribociclib was maintained through extended follow-up, further supporting its use in HR+/HER2- ABC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016474
003      
CZ-PrNML
005      
20231026105758.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13058-023-01701-9 $2 doi
035    __
$a (PubMed)37653397
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Neven, P $u Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Herestraat 49, 3000, Leuven, Belgium. patrick.neven@uzleuven.be
245    10
$a Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant / $c P. Neven, PA. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, SA. Im, K. Petrakova, GV. Bianchi, M. Martín, A. Nusch, GS. Sonke, L. De la Cruz-Merino, JT. Beck, JP. Zarate, Y. Wang, A. Chakravartty, C. Wang, DJ. Slamon
520    9_
$a BACKGROUND: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in the final protocol-specified and exploratory (longer follow-up) OS analyses. At the time of these analyses, the full OS benefit of 1L ribociclib was not completely characterized because the median OS (mOS) was not reached. As CDK4/6 inhibitor (CDK4/6i) + endocrine therapy (ET) is now a preferred option for 1L HR+/HER2- ABC, we report an exploratory analysis (median follow-up, 70.8 months; 14.5 months longer than the prior analysis) to fully elucidate the OS benefit in the MONALEESA-3 1L population. METHODS: Postmenopausal patients with HR+/HER2- ABC were randomized 2:1 to 1L/2L fulvestrant + ribociclib or placebo. OS in 1L patients (de novo disease or relapse > 12 months from completion of [neo]adjuvant ET) was assessed by Cox proportional hazards model and Kaplan-Meier methods. Progression-free survival 2 (PFS2) and chemotherapy-free survival (CFS) were analyzed. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615). RESULTS: At data cutoff (January 12, 2022; median follow-up time, 70.8 months), mOS was 67.6 versus 51.8 months with 1L ribociclib versus placebo (hazard ratio (HR) 0.67; 95% CI 0.50-0.90); 16.5% and 8.6% of ribociclib and placebo patients, respectively, were still receiving treatment. PFS2 (HR 0.64) and CFS (HR 0.62) favored ribociclib versus placebo. Among those who discontinued treatment, 16.7% and 35.0% on ribociclib or placebo, respectively, received a subsequent CDK4/6i. No new safety signals were observed. CONCLUSIONS: This analysis of MONALEESA-3 reports the longest mOS thus far (67.6 months) for 1L patients in a phase III ABC trial. These results in a 1L population show that the OS benefit of ribociclib was maintained through extended follow-up, further supporting its use in HR+/HER2- ABC.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fulvestrant $7 D000077267
650    12
$a nádory prsu $x farmakoterapie $7 D001943
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a postmenopauza $7 D017698
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fasching, P A $u University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
700    1_
$a Chia, S $u British Columbia Cancer Agency, Vancouver, BC, Canada
700    1_
$a Jerusalem, G $u CHU Liege and Liège University, Liège, Belgium
700    1_
$a De Laurentiis, M $u Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
700    1_
$a Im, S-A $u Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
700    1_
$a Petrakova, K $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Bianchi, G V $u Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
700    1_
$a Martín, M $u Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain
700    1_
$a Nusch, A $u Practice for Hematology and Internal Oncology, Velbert, Germany
700    1_
$a Sonke, G S $u Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands
700    1_
$a De la Cruz-Merino, L $u Hospital Universitario Virgen Macarena, Seville, Spain
700    1_
$a Beck, J T $u Highlands Oncology, Springdale, AR, USA
700    1_
$a Zarate, J P $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Wang, Y $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Chakravartty, A $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Wang, C $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Slamon, D J $u David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
773    0_
$w MED00006602 $t Breast cancer research : BCR $x 1465-542X $g Roč. 25, č. 1 (2023), s. 103
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37653397 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105752 $b ABA008
999    __
$a ok $b bmc $g 2000165 $s 1202836
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 1 $d 103 $e 20230831 $i 1465-542X $m Breast cancer research $n Breast Cancer Res $x MED00006602
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace